NCT06567990View on ClinicalTrials.gov

Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes

NANot yet recruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2026

Conditions

Metabolic Dysfunction-Associated Liver Disease

Interventions

DIAGNOSTIC_TEST

Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.

"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"

Trial Locations (1)

69495

Service d'Endocrinologie, Diabète et nutrition, Pierre-Bénite

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT06567990 - Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes | Biotech Hunter | Biotech Hunter